CA3279953A1 - C7, c12, and c16 substituted neuroactive steroids and their methods of use - Google Patents
C7, c12, and c16 substituted neuroactive steroids and their methods of useInfo
- Publication number
- CA3279953A1 CA3279953A1 CA3279953A CA3279953A CA3279953A1 CA 3279953 A1 CA3279953 A1 CA 3279953A1 CA 3279953 A CA3279953 A CA 3279953A CA 3279953 A CA3279953 A CA 3279953A CA 3279953 A1 CA3279953 A1 CA 3279953A1
- Authority
- CA
- Canada
- Prior art keywords
- methods
- neuroactive steroids
- substituted neuroactive
- substituted
- steroids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0029—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
- C07J7/003—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
- C07J7/006—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a hydroxy group free esterified or etherified
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360884P | 2016-07-11 | 2016-07-11 | |
| US201662360887P | 2016-07-11 | 2016-07-11 | |
| US201662360876P | 2016-07-11 | 2016-07-11 | |
| US62/360,876 | 2016-07-11 | ||
| US62/360,887 | 2016-07-11 | ||
| US62/360,884 | 2016-07-11 | ||
| CA3030420A CA3030420C (en) | 2016-07-11 | 2017-07-11 | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3030420A Division CA3030420C (en) | 2016-07-11 | 2017-07-11 | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3279953A1 true CA3279953A1 (en) | 2025-11-29 |
Family
ID=59388162
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3279953A Pending CA3279953A1 (en) | 2016-07-11 | 2017-07-11 | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| CA3030420A Active CA3030420C (en) | 2016-07-11 | 2017-07-11 | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3030420A Active CA3030420C (en) | 2016-07-11 | 2017-07-11 | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20190233465A1 (enExample) |
| EP (1) | EP3481844B1 (enExample) |
| JP (3) | JP7065825B2 (enExample) |
| AU (3) | AU2017296295B2 (enExample) |
| CA (2) | CA3279953A1 (enExample) |
| DK (1) | DK3481844T3 (enExample) |
| ES (1) | ES2992037T3 (enExample) |
| MA (1) | MA45600A (enExample) |
| NZ (3) | NZ790187A (enExample) |
| WO (1) | WO2018013615A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| CN104136452A (zh) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| SI2986624T1 (sl) | 2013-04-17 | 2020-10-30 | Sage Therapeutics, Inc. | 19-nor nevroaktivni steroidi za metode zdravljenja |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP4527461A3 (en) | 2014-10-16 | 2025-06-25 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| RS60642B1 (sr) | 2014-10-16 | 2020-09-30 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| SMT202000276T1 (it) | 2014-11-27 | 2020-07-08 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| IL264129B2 (en) | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TWI854445B (zh) | 2016-08-23 | 2024-09-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| MX2020008422A (es) * | 2018-02-11 | 2020-09-21 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos. |
| CN111040015B (zh) * | 2018-10-15 | 2022-03-18 | 南京诺瑞特医药科技有限公司 | 19-去甲-c21取代类固醇衍生物 |
| WO2020135454A1 (zh) * | 2018-12-26 | 2020-07-02 | 张家口华健致远生物科技有限公司 | 一类类固醇化合物及其用途 |
| EP3911331A4 (en) * | 2019-01-14 | 2023-01-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF |
| SG11202112391UA (en) * | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CA3143509A1 (en) * | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP7726867B6 (ja) * | 2019-08-07 | 2025-09-18 | 上▲海▼翰森生物医▲薬▼科技有限公司 | ステロイド誘導体調節因子の塩及び結晶形態 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| CN116606341A (zh) * | 2022-07-28 | 2023-08-18 | 上海醇健实业发展有限公司 | 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物 |
| WO2025175304A2 (en) * | 2024-02-16 | 2025-08-21 | Sanofi Pasteur Inc. | Process for the preparation of deoxycholic acid |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| GB1376892A (en) * | 1970-11-12 | 1974-12-11 | Glaxo Lab Ltd | 2beta-substituted-3alpha-hydroxysteroids and their esters |
| GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| DK134348C (da) | 1973-11-30 | 1977-03-21 | Schering Ag | Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| EP0263213B1 (en) * | 1986-10-09 | 1995-09-06 | The Upjohn Company | C20 Through C26 amino steroids |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| GB8804579D0 (en) | 1988-02-26 | 1988-03-30 | Akzo Nv | Novel 16-homo-piperidino-androstane derivatives & processes for their preparation |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CA2118938A1 (en) | 1991-09-13 | 1993-04-01 | Kelvin W. Gee | Novel gabaa receptor with steroid binding sites |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| EP0752860B1 (en) | 1994-02-14 | 2000-08-23 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| CA2205919A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| DE69634039T2 (de) | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| IL146230A0 (en) | 1999-04-29 | 2002-07-25 | Purdue Pharma Ltd | 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| ES2243442T3 (es) | 2000-02-18 | 2005-12-01 | Taiho Pharmaceutical Company Limited | Procedimiento de preparacion de derivados esteroides. |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| ES2287184T3 (es) | 2000-11-03 | 2007-12-16 | Washington University | Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora. |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| AU2004224053B2 (en) | 2003-03-24 | 2011-06-09 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
| WO2005000869A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| JP2007512344A (ja) | 2003-11-24 | 2007-05-17 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体調節剤 |
| US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| CA2582231A1 (en) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Steroid analogs and uses |
| RS51304B (sr) | 2005-06-09 | 2010-12-31 | Euro-Celtique S.A. | Farmaceutske kompozicije neuroaktivnog steroida i njihova upotreba |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| WO2008157460A1 (en) | 2007-06-15 | 2008-12-24 | Cook, Kevin, M. | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) * | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| EP2598513A1 (en) | 2010-07-30 | 2013-06-05 | Medexis S.A. | Compounds and methods for treating neoplasia |
| EP2667876A2 (en) | 2010-12-15 | 2013-12-04 | Harbor BioSciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| CA2828047C (en) | 2011-02-15 | 2020-03-10 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| ES2657986T3 (es) | 2011-03-23 | 2018-03-07 | Etsuro Ito | Método y kit para la medición de muy alta sensibilidad de proteína y ácido nucleico y un novedoso sustrato enzimático |
| EP2736919A4 (en) | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| CN104136452A (zh) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| DK2806877T3 (da) | 2012-01-23 | 2019-11-04 | Sage Therapeutics Inc | Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PT3336097T (pt) | 2012-06-19 | 2020-10-29 | Intercept Pharmaceuticals Inc | Preparação da forma não cristalina de ácido obeticólico |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2916846B1 (en) | 2012-11-09 | 2025-09-17 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| SI2986624T1 (sl) | 2013-04-17 | 2020-10-30 | Sage Therapeutics, Inc. | 19-nor nevroaktivni steroidi za metode zdravljenja |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| TWI839649B (zh) * | 2014-05-29 | 2024-04-21 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及其用途 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016036724A1 (en) | 2014-09-02 | 2016-03-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
| RS60642B1 (sr) | 2014-10-16 | 2020-09-30 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| EP4527461A3 (en) | 2014-10-16 | 2025-06-25 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| SMT202000276T1 (it) | 2014-11-27 | 2020-07-08 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| JP2018526423A (ja) | 2015-09-08 | 2018-09-13 | ビューポイント セラピューティクス， インコーポレイテッド | 眼科疾患を処置するための化合物および製剤 |
| MX2018004376A (es) | 2015-10-16 | 2018-08-01 | Marinus Pharmaceuticals Inc | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. |
| US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| IL264129B2 (en) | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| JP7039551B2 (ja) | 2016-07-15 | 2022-03-22 | ビーエーエスエフ ソシエタス・ヨーロピア | ３－メチル－１，５－シクロペンタデカンジオンからの１４－メチル－１６－オキサビシクロ［１０．３．１］ペンタデセンの調製 |
| TWI854445B (zh) | 2016-08-23 | 2024-09-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| CN111065394B (zh) | 2017-08-31 | 2023-03-31 | 武田药品工业株式会社 | 中枢神经系统病症的治疗 |
| AU2018327357B2 (en) | 2017-09-07 | 2024-08-22 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
| AU2019264032A1 (en) | 2018-05-04 | 2020-12-03 | Acerus Pharmaceuticals Corporation | Neurosteroid derivatives and uses thereof |
-
2017
- 2017-07-11 NZ NZ790187A patent/NZ790187A/en unknown
- 2017-07-11 US US16/316,851 patent/US20190233465A1/en not_active Abandoned
- 2017-07-11 CA CA3279953A patent/CA3279953A1/en active Pending
- 2017-07-11 DK DK17743137.6T patent/DK3481844T3/da active
- 2017-07-11 NZ NZ749714A patent/NZ749714A/en unknown
- 2017-07-11 WO PCT/US2017/041605 patent/WO2018013615A1/en not_active Ceased
- 2017-07-11 ES ES17743137T patent/ES2992037T3/es active Active
- 2017-07-11 AU AU2017296295A patent/AU2017296295B2/en active Active
- 2017-07-11 CA CA3030420A patent/CA3030420C/en active Active
- 2017-07-11 JP JP2019500826A patent/JP7065825B2/ja active Active
- 2017-07-11 EP EP17743137.6A patent/EP3481844B1/en active Active
- 2017-07-11 NZ NZ790186A patent/NZ790186A/en unknown
- 2017-07-11 MA MA045600A patent/MA45600A/fr unknown
-
2021
- 2021-04-28 US US17/242,913 patent/US11993628B2/en active Active
-
2022
- 2022-01-14 AU AU2022200247A patent/AU2022200247B2/en active Active
- 2022-04-26 JP JP2022072338A patent/JP7611186B2/ja active Active
-
2024
- 2024-02-09 AU AU2024200851A patent/AU2024200851A1/en active Pending
- 2024-04-16 US US18/636,563 patent/US20250092084A1/en active Pending
- 2024-12-23 JP JP2024226326A patent/JP2025060778A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ790187A (en) | 2025-08-29 |
| US20190233465A1 (en) | 2019-08-01 |
| US20230021308A9 (en) | 2023-01-19 |
| MA45600A (fr) | 2019-05-15 |
| CA3030420A1 (en) | 2018-01-18 |
| DK3481844T3 (da) | 2024-07-22 |
| JP7065825B2 (ja) | 2022-05-12 |
| NZ790186A (en) | 2025-08-29 |
| US20220002340A1 (en) | 2022-01-06 |
| ES2992037T3 (es) | 2024-12-05 |
| AU2017296295B2 (en) | 2022-02-24 |
| AU2024200851A1 (en) | 2024-02-29 |
| EP3481844A1 (en) | 2019-05-15 |
| US11993628B2 (en) | 2024-05-28 |
| WO2018013615A1 (en) | 2018-01-18 |
| US20250092084A1 (en) | 2025-03-20 |
| AU2022200247A1 (en) | 2022-02-10 |
| JP2022105088A (ja) | 2022-07-12 |
| JP7611186B2 (ja) | 2025-01-09 |
| EP4406602A2 (en) | 2024-07-31 |
| JP2019520417A (ja) | 2019-07-18 |
| AU2022200247B2 (en) | 2024-03-07 |
| AU2017296295A1 (en) | 2019-01-24 |
| EP3481844B1 (en) | 2024-04-17 |
| JP2025060778A (ja) | 2025-04-10 |
| NZ749714A (en) | 2025-08-29 |
| CA3030420C (en) | 2025-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3279953A1 (en) | C7, c12, and c16 substituted neuroactive steroids and their methods of use | |
| IL273099A (en) | Neuroactive steroids and methods of using them | |
| IL283629A (en) | Neuroactive steroids and methods of using them | |
| IL266353A (en) | Steroids and their protein conjugates | |
| IL261658A (en) | Neuroactive steroids, preparations and their uses | |
| IL255801A (en) | Liposomal nanoconstructs and methods of making and using the same | |
| HUE050028T2 (hu) | Neuroaktív szteroidok, készítmények és alkalmazásuk | |
| SG11202001125XA (en) | Self-aligned high aspect ratio structures and methods of making | |
| EP3280441A4 (en) | Anti-sortilin antibodies and methods of use thereof | |
| PL3545080T3 (pl) | Mikrokompartment komórkowy i sposoby jego przygotowania | |
| EP3595853A4 (en) | COMPOSITE STRUCTURES AND PROCESSES FOR FORMING COMPOSITE STRUCTURES | |
| ZA201708412B (en) | Neuroactive steroid solutions and their methods of use | |
| EP3285805A4 (en) | Therapeutic antibodies and uses thereof | |
| EP3283493A4 (en) | Texaphyrin-phospholipid conjugates and methods of preparing same | |
| EP3233124A4 (en) | Nanowire-coated microdevice and method of making and using the same | |
| EP3221597A4 (en) | Wall-mountable assembly and method of use | |
| EP3227298A4 (en) | Process for the preparation of baricitinib and an intermediate thereof | |
| ZA202100093B (en) | Neuroactive steroids and methods of preparation | |
| EP3334730A4 (en) | Pyrrolomycins and methods of using the same | |
| IL246944B (en) | A process for the preparation of abiraterone acetate and its intermediates | |
| EP3203930A4 (en) | Tissue integration devices and methods of making the same | |
| EP3504267B8 (en) | Oligoesters compositions and methods of making and using same | |
| EP3436426A4 (en) | IMPROVED PROCESS FOR THE PREPARATION OF DROXIDOPA AND ITS INTERMEDIATE | |
| EP3180440A4 (en) | Yeast preparations and methods of making the same | |
| EP3307251B8 (en) | Fluorocyclopentenylcytosine uses and processes of preparation |